FDA Places Clinical Hold on Second Idenix Hepatitis Drug
The FDA has placed a “precautionary” clinical hold on Idenix Pharmaceutical’s next-generation nucleotide polymerase inhibitor, IDX19368, being developed to treat hepatitis C (HCV) infection.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.